source
- J&J reports 40% Q2 sales jump for Spravato as psychedelic rivals loomJohnson & Johnson said its depression nasal spray Spravato generated $584 million in worldwide revenue in the second quarter, a 40% increase from a year earlier. The company highlighted the drug as…
- Amylyx to read out pivotal endocrine drug study results later this quarterAmylyx Pharmaceuticals will read out results later this quarter from a study of a new treatment for a rare endocrine disorder. The drug, avexitide, is being developed to prevent severe, uncontroll…